| Dr Robert H Fleming, MD | |
|
2237 Keystone Circle, Andover, KS 67002 | |
| (316) 616-6272 | |
| (316) 616-0407 |
| Full Name | Dr Robert H Fleming |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 37 Years |
| Location | 2237 Keystone Circle, Andover, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770542961 | NPI | - | NPPES |
| 100158280C | Medicaid | KS | |
| 200426030A | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 0424941 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hutchinson Regional Medical Center Inc | Hutchinson, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hutchinson Regional Medical Center Inc | 0648181198 | 53 |
News Archive
The results of the much awaited BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have shown that coronary artery disease (CAD) patients with left ventricular dysfunction (LVD) and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients (heart rate above 70 bpm) treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.
Scientists from The Scripps Research Institute have shed new light on a molecular switch that turns genes on or off in response to a cell's energy needs.
A Professor at Durham University's School of Education has sparked a major debate about the status of dyslexia and the value of labelling of some people with reading problems as "dyslexic".
MAP Pharmaceuticals, Inc. today announced that LEVADEX orally inhaled migraine drug will be featured in four poster presentations, including one late-breaker presentation, at the 15th Congress of the International Headache Society (IHC) in Berlin, Germany on June 23-26, 2011.
› Verified 8 days ago
| Entity Name | Hutchinson Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972605285 PECOS PAC ID: 0648181198 Enrollment ID: O20040119000578 |
News Archive
The results of the much awaited BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have shown that coronary artery disease (CAD) patients with left ventricular dysfunction (LVD) and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients (heart rate above 70 bpm) treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.
Scientists from The Scripps Research Institute have shed new light on a molecular switch that turns genes on or off in response to a cell's energy needs.
A Professor at Durham University's School of Education has sparked a major debate about the status of dyslexia and the value of labelling of some people with reading problems as "dyslexic".
MAP Pharmaceuticals, Inc. today announced that LEVADEX orally inhaled migraine drug will be featured in four poster presentations, including one late-breaker presentation, at the 15th Congress of the International Headache Society (IHC) in Berlin, Germany on June 23-26, 2011.
› Verified 8 days ago
| Entity Name | Cedar Surgical Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336289123 PECOS PAC ID: 2365546835 Enrollment ID: O20070323000137 |
News Archive
The results of the much awaited BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have shown that coronary artery disease (CAD) patients with left ventricular dysfunction (LVD) and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients (heart rate above 70 bpm) treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.
Scientists from The Scripps Research Institute have shed new light on a molecular switch that turns genes on or off in response to a cell's energy needs.
A Professor at Durham University's School of Education has sparked a major debate about the status of dyslexia and the value of labelling of some people with reading problems as "dyslexic".
MAP Pharmaceuticals, Inc. today announced that LEVADEX orally inhaled migraine drug will be featured in four poster presentations, including one late-breaker presentation, at the 15th Congress of the International Headache Society (IHC) in Berlin, Germany on June 23-26, 2011.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert H Fleming, MD 2237 Keystone Circle, Andover, KS 67002 Ph: (316) 616-6272 | Dr Robert H Fleming, MD 2237 Keystone Circle, Andover, KS 67002 Ph: (316) 616-6272 |
News Archive
The results of the much awaited BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have shown that coronary artery disease (CAD) patients with left ventricular dysfunction (LVD) and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients (heart rate above 70 bpm) treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.
Scientists from The Scripps Research Institute have shed new light on a molecular switch that turns genes on or off in response to a cell's energy needs.
A Professor at Durham University's School of Education has sparked a major debate about the status of dyslexia and the value of labelling of some people with reading problems as "dyslexic".
MAP Pharmaceuticals, Inc. today announced that LEVADEX orally inhaled migraine drug will be featured in four poster presentations, including one late-breaker presentation, at the 15th Congress of the International Headache Society (IHC) in Berlin, Germany on June 23-26, 2011.
› Verified 8 days ago
Baylee Elise Ehrhart, APRN Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: May Accept Medicare Assignments Practice Location: 2237 Keystone Cir, Andover, KS 67002 Phone: 316-616-6272 | |
Dr. Badr Idbeis, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: May Accept Medicare Assignments Practice Location: 2237 Keystone Circle, Andover, KS 67002 Phone: 316-616-6272 Fax: 316-616-0407 |